Data from Lundbeck’s Phase 2 and 3 clinical trials of idalopirdine in Alzheimer’s patients, will be made available to researchers worldwide through the Critical Path for Alzheimer’s Disease (CPAD) consortium database, held by The Critical Path Institute (C-Path). The Phase 3 studies failed to meet their primary goals of improving cognitive abilities in those given this treatment. C-Path is…
“As iron sharpens iron, so one person sharpens another.” –King Solomon This COVID-19 journey has become a long one. Did any of us have an idea it would go this far? I doubt it, and yet here we are. Some of us might be a little worse for wear, but my hope is that we’re…
Axsome Therapeutics is planning to complete its ADVANCE-1 clinical trial, evaluating AXS-05 as a treatment for agitation in Alzheimer’s disease, a few months earlier to ensure the safety of study participants during the COVID-19 pandemic. Topline results from this Phase 2/3 trial, which opened in 2017, are now expected in April or May, rather than later this…
Turning our attention away from the all-intrusive pandemic (at least from the primary topics surrounding COVID-19), it’s good to take a minute from the turmoil of the virus to engage with something positive. The continual waves of uncertainty that drive COVID-19 may leave something positive in the disease’s painful wake, particularly for people with Alzheimer’s…
Because the COVID-19 pandemic has many people staying at home, the Alzheimer’s Foundation of America (AFA) has suggestions about activities to help patients and their families stay active and engaged. “Stimulating the brain is beneficial both for individuals living with Alzheimer’s disease and their caregivers,” Charles J. Fuschillo Jr., AFA president and CEO, said in…
Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance related to the COVID-19 pandemic. A Phase 2 study of people with dementia linked to Parkinson’s disease is fully enrolled, and the company expects to announce topline results…
“Gratitude turns what we have into enough.” — Anonymous If you’re like a lot of people, the COVID-19 pandemic is the first thing that comes to mind when you awaken, and possibly the last penetrating thought before bedtime. Though we tire of its bad news, we can’t turn away. Like a train wreck, or a terrible…
A new analysis of data from a Phase 3 clinical trial testing the blood pressure medication nilvadipine supports evidence that its use helps to slow cognitive decline in Alzheimer’s patients with very mild, very early stage disease. This finding was reported earlier — the trial ended in 2016 — but results then looked at the entire trial population, ranging from…
Moderate lifetime alcohol intake in middle-aged and older people who don’t show signs of dementia is associated with lower deposits of amyloid-beta, the protein that forms toxic aggregates in the brain and is thought to be involved in the onset of Alzheimer’s disease, a study from Korea found. The study, “Association of moderate alcohol intake…
Caregivers are the first line of defense between their loved ones and, well, everything. Like everyone on the planet, our brains are steeped with thoughts of the coronavirus. It’s our job to stand between our loved ones and the communicable disease, but it’s also our responsibility to keep them from becoming overwrought by all the…
